Journal Title：Expert Review Of Hematology

Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.

近年來，先進(jìn)的分子研究技術(shù)已經(jīng)改變了血液學(xué)。隨著對血液病的了解不斷加深，我們現(xiàn)在有機會研究和評估新的生物療法、新藥物和藥物組合、新的治療方案和包括干細(xì)胞移植在內(nèi)的新方法。我們還可以期待蛋白質(zhì)組學(xué)、分子遺傳學(xué)和生物標(biāo)志物研究能夠促進(jìn)新的診斷方法和適當(dāng)療法的識別。我們對血細(xì)胞和造血組織的形成和功能的認(rèn)識將進(jìn)一步提高，對于血液學(xué)家來說，采用這些新模式并制定綜合策略來確定最佳的患者護(hù)理將是一個重大挑戰(zhàn)?！堆簩W(xué)專家評論》（1747-4086）將這些進(jìn)展放在背景中，并探討它們將如何直接轉(zhuǎn)化為臨床實踐。

Expert Review Of Hematology創(chuàng)刊于2008年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋HEMATOLOGY全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過審相對較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)2.3，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。